Gotu Kola (Centella asiatica) vs NSI-189

Mechanism

Pentacyclic triterpenes — asiaticoside, madecassoside, asiatic acid, and madecassic acid — provide neuroprotection through multiple mechanisms: inhibition of acetylcholinesterase activity and enhancement of cholinergic transmission; reduction of phospholipase A2 (PLA2) activity to attenuate neuroinflammation; protection against beta-amyloid aggregation and tau hyperphosphorylation; and upregulation of BDNF to promote neuronal growth and synaptic plasticity. Asiaticoside enhances collagen synthesis and wound healing, while asiatic acid activates the MAPK/ERK pathway to promote neurite outgrowth.

Standard Dosing

500-1000 mg/day of standardized extract (35-45% triterpenes) or 750-1500 mg/day of whole herb extract

Timing

Morning or split morning/afternoon. With or without food. Acute mood effects (alertness, reduced anger) noted within 1 hour of dosing.

Cycle Duration

Ongoing; traditional use suggests no cycling required. Clinical trials run 2-6 months.

Side Effects

• GI discomfort
• Drowsiness
• Headache
• Skin irritation (topical use)
• Hepatotoxicity (rare, with prolonged high-dose use)

Contraindications

• Pregnancy (traditionally contraindicated; may have emmenagogue effects)
• Hepatic disease (rare hepatotoxicity reported)
• Scheduled surgery (may affect wound healing dynamics)

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners